Prospects for use of platelet-rich plasma in the treatment of rheumatoid arthritis
https://doi.org/10.14412/1996-7012-2021-1-87-93
Abstract
The paper reviews the data available in the literature on the mechanisms of action of platelet-rich plasma (PRP) and the experience of its use in patients with rheumatoid arthritis (RA). It defines the place of PRP in the systemic and local therapy of RA. The chemical composition of PRP and the structure of the platelet organelles included in it are described. An estimate is made for procedures to prepare platelet-rich plasma containing different concentrations of key growth factors, such as platelet-derived growth factor (PDGF), transforming growth factor α (TGFα), vascular endothelial growth factor (VEGF), insulin-like growth factor (IGF), and epidermal growth factor (EGF). The variants of PRP classifications, which take into account differences in the composition and levels of the growth factors, are considered. The experience with intra-articular injections of autologous plasma products in patients with RA and synovitis is analyzed. These findings lead to the conclusion that PRP therapy can be an effective tool to relieve inflammation and to stimulate local reparative processes in damaged joint tissues in patients with RA. Further study of the possibilities of using this method of therapy and the formation of a PRPtherapy protocol for patients with rheumatoid arthritis will provide effective personalized care to these patients.
About the Authors
S. V. Maglevaniy
V.A. Nasonova Research Institute of Rheumatology
Russian Federation
Russian Federation
Sergey Vladimirovich Maglevaniy
34A, Kashirskoe Shosse, Moscow 115522
E. A. Naryshkin
V.A. Nasonova Research Institute of Rheumatology
Russian Federation
Russian Federation
34A, Kashirskoe Shosse, Moscow 115522
E. V. Chetina
V.A. Nasonova Research Institute of Rheumatology
Russian Federation
Russian Federation
34A, Kashirskoe Shosse, Moscow 115522
M. A. Makarov
V.A. Nasonova Research Institute of Rheumatology
Russian Federation
Russian Federation
34A, Kashirskoe Shosse, Moscow 115522
References
1. Nasonov EL, Karateev DE, Balabanova RM. Rheumatoid arthritis. In: NasonovEL, Nasonova VA, editors. Revmatologiya. Natsional'noe rukovodstvo [Rheumatology. National guidelines]. Moscow: GEOTARMedia; 2008. P. 290-331.
2. Bartok B, Firestein GS. Fibroblast-like synoviocytes: key effector cells in rheumatoid arthritis. Immunol Rev. 2010 Jan;233(1):233- 55. doi: 10.1111/j.0105-2896.2009.00859.x.
3. Orr C, Vieira-Sousa E, Boyle DL, et al. Synovial tissue research: a state-of-the-art review. Nat Rev Rheumatol. 2017 Aug;13(8): 463-75. doi:10.1038/nrrheum.2017.115. Epub 2017 Jul 13.
4. Elshabrawy HA, Chen Z, Volin MV, et al. The pathogenic role of angiogenesis in rheumatoid arthritis. Angiogenesis. 2015 Oct; 18(4):433-48. doi: 10.1007/s10456-015-9477-2. Epub 2015 Jul 22.
5. Fang Q, Ou J, Nandakumar KS. Autoantibodies as Diagnostic Markers and Mediator of Joint Inflammation in Arthritis. Mediators Inflamm. 2019 Oct 27;2019: 6363086. doi: 10.1155/2019/6363086. eCollection 2019.
6. Monaco C, Nanchahal J, Taylor P, Feldmann M. Anti-TNF therapy: past, present and future. Int Immunol. 2015 Jan; 27(1):55-62. doi: 10.1093/intimm/dxu102. Epub 2014 Nov 19.
7. Nasonov EL. Pharmacotherapy for rheumatoid arthritis: New strategy, new targets. Nauchno-prakticheskaya revmatologiya. 2017;55(4):409-19. (In Russ.).
8. Korhonen R, Moilanen E. Abatacept, a novel CD80/86-CD28 T cell co-stimulation modulator, in the treatment of rheumatoid arthritis. Basic Clin Pharmacol Toxicol. 2009 Apr;104(4):276-84. doi: 10.1111/j.1742-7843.2009.00375.x. Epub 2009 Feb 18.
9. Dayer JM, Feige U, Edwards CK 3rd, et al. Anti-interleukin-1 therapy in rheumatic diseases. Curr Opin Rheumatol. 2001 May;13(3): 170-6. doi: 10.1097/00002281-200105000-00004.
10. Nasonov EL. New areas of the pharmacotherapy of rheumatic diseases are inhibition of interleukin-6 and interleukin-17. Sovremennaya revmatologiya = Modern Rheumatology Journal. 2013;7(3):5-14. (In Russ.). doi: 10.14412/1996-7012-2013-04
11. Olyunin YuA. Intra-articular drug injections in the combination treatment of rheumatic diseases. Sovremennaya revmatologiya = Modern Rheumatology Journal. 2015;9(1): 78-83. (In Russ.). doi: 10.14412/1996-7012-2015-1-78-83
12. Af Klint E, Grundtman C, Engström M, et al. Intraarticular glucocorticoid treatment reduces inflammation in synovial cell infiltrations more efficiently than in synovial blood vessels. Arthritis Rheum. 2005 Dec;52(12): 3880-89. doi: 10.1002/art.21488
13. Gheorghe KR, Korotkova M, Catrina AI, et al. Expression of 5-lipoxygenase and 15-lipoxygenase in rheumatoid arthritis synovium and effects of intraarticular glucocorticoids. Arthritis Res Ther. 2009;11(3):R83. doi: 10.1186/ar2717. Epub 2009 Jun 4.
14. Nikas SN, Temekonidis TI, Zikou AK, et al. Treatment of resistant rheumatoid arthritis by intra-articular infliximab injections: a pilot study. Ann Rheum Dis. 2004 Jan;63(1):102-3. doi: 10.1136/ard.2003.006981
15. Zhang F, Ma C. Comparison of the effectiveness on intra-articular and subcutaneous TNF inhibitor in rheumatoid arthritis patients. Clin Rheumatol. 2018 Jan;37(1): 199-204. doi: 10.1007/s10067-017-3806-3. Epub 2017 Sep 4.
16. Mortada MA, Abdelwhab SM, Elgawish MH. Intra-articular methotrexate versus corticosteroid injections in medium-sized joints of rheumatoid arthritis patients-an intervention study. Clin Rheumatol. 2018 Feb; 37(2):331-7. doi: 10.1007/s10067-017-3843-y. Epub 2017 Sep 30.
17. Saito S, Kotake S. Is there evidence in support of the use of intra-articular hyaluronate in treating rheumatoid arthritis of the knee? A meta-analysis of the published literature. Mod Rheumatol. 2009;19(5):493-501. doi: 10.1007/s10165-009-0189-6. Epub 2009 Jun 23.
18. Vasil'ev SA, Berkovskii AL, Melkumyan AL. Posobie po izucheniyu funktsii trombotsitov. Norma i patologiya [Manual for the study of platelet function. Norm and pathology]. Moscow; 2017. P. 9-12.
19. Lippi G, Franchini M. Platelets and immunity: the interplay of mean platelet volume in health and disease. Expert Rev Hematol. 2015 Oct;8(5):555-7. doi: 10.1586/17474086.2015.1069703. Epub 2015 Jul 15.
20. Nurden A. Platelets, inflammation and tissue regeneration. Thromb Haemost. 2011 May;105 Suppl 1:S13-33. doi: 10.1160/THS10-11-0720. Epub 2011 Apr 11.
21. Raposo G, Marks MS, Cutler DF. Lysosome-related organelles: driving postGolgi compartments into specialisation. Curr Opin Cell Biol. 2007 Aug;19:394-401 doi: 10.1016/j.ceb.2007.05.001. Epub 2007 Jul 12.
22. Ambrosio AL, Di Pietro SM. Storage pool diseases illuminate platelet dense granule biogenesis. Platelets. 2017 Mar;28(2):138- 146. doi: 10.1080/09537104.2016.1243789. Epub 2016 Nov 16.
23. Flaumenhaft R, Koseoglu S. Platelet Contents. In: Schulze H, Italiano J, editors. Molecular and Cellular Biology of Platelet Formation. Cham: Springer; 2016.
24. Scully D, Naseem KM, Matsakas A. Platelet biology in regenerative medicine of skeletal muscle. Acta Physiol (Oxf). 2018 Jul; 223(3):e13071. doi: 10.1111/apha.13071. Epub 2018 Apr 19.
25. Akhundov K, Pietramaggiori G, Waselle L, et al. Development of a cost-effective method for platelet-rich plasma (PRP) preparation for topical wound healing. Ann Burns Fire Disasters. 2012 Dec 31;25(4):207-13.
26. Oudelaar BW, Peerbooms JC, Huis In't Veld R, et al. Concentrations of blood components in commercial platelet-rich plasma separation systems: a review of the literature. Am J Sports Med. 2019 Feb;47(2):479-87. doi: 10.1177/0363546517746112. Epub 2018 Jan 16.
27. Samra DJ, Orchard JW. Patterns of platelet-rich plasma use among Australasian sports physicians. BMJ Open Sport Exerc Med. 2015 Nov 9;1(1):e000054. doi: 10.1136/bmjsem-2015-000054. eCollection 2015.
28. Dohan Ehrenfest DM, Rasmusson L, Albrektsson T. Classification of platelet concentrates: From pure platelet-rich plasma (P-PRP) to leucocyte- and platelet-rich fibrin (L-PRF). Trends Biotechnol. 2009 Mar; 27(3):158-67. doi: 10.1016/j.tibtech.2008.11.009. Epub 2009 Jan 31.
29. Magalon J, Chateau AL, Bertrand B, et al. DEPA classification: a proposal for standardising PRP use and a retrospective application of available devices. BMJ Open Sport Exerc. Med. 2016 Feb;2(1):e000060. doi: 10.1136/bmjsem-2015-000060. eCollection 2016.
30. Lana JFSD, Purita J, Paulus C, et al. Contributions for classification of platelet rich plasma - proposal of a new classification: MARSPILL. Regen Med. 2017 Jul;12(5): 565-74. doi: 10.2217/rme-2017-0042. Epub 2017 Jul 31.
31. Piao L, Park H, Jo CH. Theoretical prediction and validation of cell recovery rates in preparing platelet-rich plasma through a centrifugation. PLoS One. 2017 Nov 2;12(11): e0187509. doi: 10.1371/journal.pone.0187509. eCollection 2017.
32. Kushida S, Kakudo N, Morimoto N, et al. Platelet and growth factor concentrations in activated platelet-rich plasma: a comparison of seven commercial separation systems. J Artif Organs. 2014 Jun;17(2):186-92. doi: 10.1007/s10047-014-0761-5. Epub 2014 Apr 20.
33. Kameyoshi Y, Dö rschner A, Mallet AI, et al. Cytokine RANTES released by thrombin-stimulated platelets is a potent attractant for human eosinophils. J Exp Med. 1992 Aug 1;176(2):587-92. doi: 10.1084/jem.176.2.587
34. Tohidnezhad M, Bayer A, Rasuo B, et al. Platelet-Released Growth Factors Modulate the Secretion of Cytokines in Synoviocytes under Inflammatory Joint Disease. Mediators Inflamm. 2017;2017:1046438. doi: 10.1155/2017/1046438. Epub 2017 Nov 19.
35. Passaretti F, Tia M, D'Esposito V, et al. Growth-promoting action and growth factor release by different platelet derivatives. Platelets. 2014;25(4):252-6. doi: 10.3109/09537104.2013.809060. Epub 2013 Jul 15.
36. Mishra A, Tummala P, King A, et al. Buffered platelet-rich plasma enhances mesenchymal stem cell proliferation and chondrogenic differentiation. Tissue Eng Part C Methods. 2009 Sep;15(3):431-5 doi: 10.1089/ten.tec.2008.0534
37. Krü ger JP, Hondke S, Endres M, et al. Human platelet-rich plasma stimulates migration and chondrogenic differentiation of human subchondral progenitor cells. J Orthop Res. 2012 Jun;30(6):845-52. doi: 10.1002/jor.22005. Epub 2011 Nov 4.
38. Cognasse F, Hamzeh-Cognasse H, Lafarge S, et al. Human platelets can activate peripheral blood B cells and increase production of immunoglobulins. Exp Hematol. 2007 Sep;35 (9):1376-87. doi: 10.1016/j.exphem.2007.05.021. Epub 2007 Jul 25.
39. Koupenova M, Clancy L, Corkrey HA, et al. Circulating platelets as mediators of immunity, inflammation, and thrombosis. Circ Res. 2018 Jan 19;122(2):337-51. doi: 10.1161/CIRCRESAHA.117.310795
40. Yeung J, Li W, Holinstat M. Platelet signaling and disease: targeted therapy for thrombosis and other related diseases. Pharmacol Rev. 2018 Jul;70(3):526-48. doi: 10.1124/pr.117.014530
41. Gasparyan AY, Ayvazyan L, Pretorius E. Platelets in rheumatic diseases: friend or foe? Curr Pharm Des. 2014;20(4):552-66. doi: 10.2174/138161282004140213143843.
42. Matsuno H. Remarkable efficacy of tocilizumab for treating rheumatoid arthritis in patients with high platelet counts. Mod Rheumatol. 2015 Jan;25(1):38-42. doi: 10.3109/14397595.2014.915073.
43. Zamora C, Canto E, Nieto JC, et al. Binding of Platelets to Lymphocytes: A Potential Anti-Inflammatory Therapy in Rheumatoid Arthritis. J Immunol. 2017 Apr 15;198(8):3099-108. doi: 10.4049/jimmunol.1601708. Epub 2017 Mar 1.
44. Gasparyan AY, Ayvazyan L, Mukanova U, et al. The Platelet-to-Lymphocyte Ratio as an Inflammatory Marker in Rheumatic Diseases. Ann Lab Med. 2019 Jul;39(4): 345-57. doi: 10.3343/alm.2019.39.4.345
45. Franck H, Rau R, Herborn G. Thrombocytopenia in patients with rheumatoid arthritis on long-term treatment with low dose methotrexate. Clin Rheumatol. 1996 May; 15(3):266-70. doi: 10.1007/BF02229705
46. Alsousou J, Thompson M, Harrison P, et al. Effect of platelet-rich plasma on healing tissues in acute ruptured Achilles tendon: a human immunohistochemistry study. Lancet. 2015 Feb 26;385 Suppl 1:S19. doi: 10.1016/S0140-6736(15)60334-8
47. Braun HJ, Wasterlain AS, Dragoo JL. The use of PRP in ligament and meniscal healing. Sports Med Arthrosc Rev. 2013 Dec; 21(4):206-12. doi: 10.1097/JSA.0000000000000005
48. Zhou Y, Wang JH. PRP Treatment Efficacy for Tendinopathy: A Review of Basic Science Studies. Biomed Res Int. 2016;2016: 9103792. doi: 10.1155/2016/9103792. Epub 2016 Aug 16.
49. Kim SJ, Yeo SM, Noh SJ, et al. Effect of platelet-rich plasma on the degenerative rotator cuff tendinopathy according to the compositions. J Orthop Surg Res. 2019 Dec;14(1): 408. doi: 10.1186/s13018-019-1406-4
50. Lim W, Park SH, Kim B, et al. Relationship of cytokine levels and clinical effect on platelet-rich plasma-treated lateral epicondylitis. J Orthop Res. 2018 Mar;36(3):913-20. doi: 10.1002/jor.23714. Epub 2017 Sep 20.
51. Shichao T, Ji L, Changqing Z. Plateletrich plasma inhibits inflammatory factors and represses rheumatoid fibroblast-like synoviocytes in rheumatoid arthritis. Clin Exp Med. 2017 Nov;17(4):441-9. doi: 10.1007/s10238-017-0449-2. Epub 2017 Jan 24.
52. Jin CH, Chae SY, Kim TH, et al. Effect of tumor necrosis factor-related apoptosisinducing ligand on the reduction of joint inflammation in experimental rheumatoid arthritis. J Pharmacol Exp Ther. 2010 Mar; 332(3):858-65. doi: 10.1124/jpet.109.159517. Epub 2009 Nov 20.
53. Yao Q, Seol DW, Mi Z, et al. Intra-articular injection of recombinant TRAIL induces synovial apoptosis and reduces inflammation in a rabbit knee model of arthritis. Arthritis Res Ther. 2006;8(1):R16. doi: 10.1186/ar1867.
54. Ichikawa K, Liu W, Fleck M, et al. TRAIL-R2 (DR5) mediates apoptosis of synovial fibroblasts in rheumatoid arthritis. J Immunol. 2003 Jul 15;171(2):1061-9. doi: 10.4049/jimmunol.171.2.1061
55. Chyuan IT, Tsai HF, Liao HJ, et al. An apoptosis-independent role of TRAIL in suppressing joint inflammation and inhibiting T-cell activation in inflammatory arthritis. Cell Mol Immunol. 2018 Sep;15(9):846-57. doi: 10.1038/cmi.2017.2. Epub 2017 Apr 10.
56. Lippross S, Moeller B, Haas H, et al. Intraarticular injection of platelet-rich plasma reduces inflammation in a pig model of rheumatoid arthritis of the knee joint. Arthritis Rheum. 2011 Nov;63(11):3344-53. doi: 10.1002/art.30547
57. Nadia A, Asmaa M. Anti-arthritic Effects of Platelets Rich Plasma and Hyaluronic Acid on Adjuvant-induced Arthritis in Rats. International Journal of Pharmacology. 2020;16:33-46; doi: 10.3923/ijp.2020.33.46
58. Badsha H, Harifi G, Murrell WD. Platelet Rich Plasma for Treatment of Rheumatoid Arthritis: Case Series and Review of Literature. Case Rep Rheumatol. 2020 Jan 31;2020:8761485. doi: 10.1155/2020/8761485. eCollection 2020.
59. Latalski M, Walczyk A, Fatyga M, et al. Allergic reaction to platelet-rich plasma (PRP): Case report. Medicine (Baltimore). 2019 Mar;98(10):e14702. doi: 10.1097/MD.0000000000014702
60. Shanshan Y, BinZhou Y, Chen S. Platelet-rich plasma promotes the migration and invasion of synovial fibroblasts in patients with rheumatoid arthritis. Mol Med Rep. 2016 Sep;14(3):2269-75. doi: 10.3892/mmr.2016.5500. Epub 2016 Jul 11.
Review
For citations:
Maglevaniy SV, Naryshkin EA, Chetina EV, Makarov MA. Prospects for use of platelet-rich plasma in the treatment of rheumatoid arthritis. Sovremennaya Revmatologiya=Modern Rheumatology Journal. 2021;15(1):87-93. https://doi.org/10.14412/1996-7012-2021-1-87-93
Views:
1657
Email this article 